FDA Warns Telehealth Companies Over Compounded GLP-1 Drugs

FDA Warns Telehealth Companies Over Compounded GLP-1 Drugs

The U.S. Food and Drug Administration has intensified its oversight of compounded GLP-1 receptor agonist medications by sending warning letters to several telehealth companies. These firms have been distributing unapproved versions of drugs such as semaglutide and tirzepatide, which are FDA-approved for managing type 2 diabetes and chronic weight management. The agency’s recent actions focus on companies that may be producing compounded copies of these medications in ways that violate federal drug compounding laws.

Compounded drugs are not FDA-approved. They do not undergo the same rigorous safety, efficacy, and quality reviews that approved medications receive. The FDA has stated that some telehealth companies appear to be compounding GLP-1 drugs despite the availability of FDA-approved versions, raising legal and safety concerns.

The Science Behind GLP-1 Receptor Agonists

GLP-1 receptor agonists mimic the action of the natural hormone glucagon-like peptide-1. This incretin hormone is released from the gut after eating, stimulating insulin secretion, suppressing glucagon release, slowing gastric emptying, and promoting satiety. Both semaglutide (marketed as Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound) have shown strong efficacy in lowering blood glucose and supporting weight loss in clinical trials, including the STEP program for semaglutide.

The demand for these drugs has skyrocketed over the past two years, driven by their success in weight management. This surge has led to intermittent shortages of the brand-name products, which in turn has created a market for compounded versions. Under federal law, compounding pharmacies may produce copies of FDA-approved drugs only when the approved product is not available to meet specific patient needs, such as during a documented shortage. However, the FDA has expressed concern that some compounders are overstepping these boundaries.

Regulatory Framework for Compounding

Compounding pharmacies in the United States operate under two primary designations. 503A pharmacies prepare individualized medications based on a prescription for a specific patient. 503B outsourcing facilities can produce larger batches without patient-specific prescriptions but must comply with current good manufacturing practices and are subject to FDA inspections.

For a compounded drug to be legal, it must be a “copy” of an FDA-approved drug only when that drug is in shortage or when the patient has a documented medical need that the approved version cannot meet, such as an allergy to an excipient. The FDA maintains a list of bulk drug substances that can be used in compounding, and neither semaglutide nor tirzepatide currently appear on that list. This means compounders may be using forms of the active ingredient not found in the approved products, such as semaglutide sodium or semaglutide acetate, which have different chemical structures, stability profiles, and safety data compared to the base drug.

In 2023, the FDA issued separate warnings about compounded semaglutide containing salt forms that are not the same as the FDA-approved semaglutide. These salt forms have not been evaluated for safety and effectiveness. The agency noted reports of adverse events including dosing errors and infections linked to compounded semaglutide. Such problems can arise from improper compounding practices, errors in potency, sterility breaches, or contamination.

Telehealth Companies Under Scrutiny

The FDA’s latest warning letters target specific telehealth companies, though the agency has not publicly named all recipients. These platforms have become a popular channel for patients seeking compounded GLP-1s, often at significantly lower prices than brand-name versions. Telehealth consultations, typically conducted online without a prior in-person relationship, have raised additional questions about appropriate medical supervision.

During the periods of shortage, compounding pharmacies are permitted to produce versions of the drugs, but only under the conditions outlined in the Federal Food, Drug, and Cosmetic Act. The FDA has indicated that some telehealth firms may be producing compounded versions even when the approved products are available, which would violate the law. The agency is also concerned that the compounding may involve large-scale production that goes beyond what is allowable for 503A pharmacies, effectively operating as unapproved drug manufacturers.

“Compounded drugs are not FDA-approved and do not undergo the same safety, efficacy, and quality reviews as approved medications,” the agency noted in its communications. The warning letters typically require companies to respond within 15 working days, explaining how they will correct the violations. Failure to do so can lead to further enforcement actions, including injunctions, product seizures, or even criminal penalties.

Risks for Patients Using Compounded GLP-1s

The FDA advises patients to be aware that compounded GLP-1 medications carry inherent risks. Without the standardized manufacturing processes used for approved drugs, compounded products may vary in potency, sterility, and purity. Previous adverse event reports linked to compounded semaglutide have included dosing errors that led to hypoglycemia or gastrointestinal distress, as well as injection site infections from contamination.

Because compounded drugs are not reviewed by the FDA, their long-term safety and effectiveness are not established. Patients who are considering compounded GLP-1s should discuss the risks and benefits with their healthcare provider. The agency encourages patients to only receive compounded medications from state-licensed pharmacies or FDA-registered outsourcing facilities that follow good manufacturing practices.

Current Status and Next Steps

As of the latest update, the FDA has not issued a recall of any specific compounded GLP-1 products in connection with these warning letters. The agency continues to monitor the market and may take additional actions as needed. Telehealth companies that received letters must now either come into compliance or face escalating enforcement.

The situation underscores a broader tension between patient access and drug safety. Compounding has historically played a vital role in providing medications for patients with unique needs, but the mass production of copies of popular drugs during shortages poses regulatory challenges. The FDA’s actions signal a renewed commitment to ensuring that the compounding exception is not abused, particularly for high-demand drugs with significant safety concerns.

Health experts recommend that patients verify their compounding pharmacy’s license and ask whether it uses FDA-registered bulk drug substances. They should also be aware that the active ingredient in a compounded GLP-1 may differ chemically from the approved drug, which could affect how it works in the body.

Frequently Asked Questions

Q: Are compounded GLP-1 drugs safe to use?

A: Compounded GLP-1 drugs are not FDA-approved and have not undergone the same quality, safety, and efficacy reviews. They may carry risks related to potency, sterility, and contamination. The FDA has received reports of dosing errors and infections associated with compounded semaglutide. Patients should talk to their healthcare provider about whether a compounded version is appropriate for their specific situation.

Q: Can I get compounded GLP-1 medications from a telehealth company?

A: Some telehealth platforms offer compounded GLP-1s, especially during shortages of brand-name products. However, the FDA has warned that some telehealth firms may be distributing these drugs in violation of federal law. If you obtain a compounded medication, ensure the pharmacy is state-licensed or registered as a 503B outsourcing facility, and verify that the drug was compounded to meet a specific medical need that cannot be addressed by an approved product.

Q: What should I do if I am taking a compounded GLP-1 drug?

A: Continue taking it as prescribed, but inform your healthcare provider that you are using a compounded version. Watch for any unusual side effects, such as signs of infection at the injection site, unusually severe gastrointestinal symptoms, or hypoglycemia. Report any adverse events to the FDA’s MedWatch program. You may also ask your pharmacy for documentation showing the source and purity of the active ingredient.

Q: Why are the FDA’s warning letters important?

A: The letters serve as a formal notice that the companies are violating federal compounding regulations. They require the firms to correct their practices or face further legal action. This enforcement helps protect patients from potentially unsafe or ineffective drugs and ensures that compounding remains a limited exception rather than a broad alternative to approved medicines.